Compliance with hormone replacement therapy (HRT) after screening for post menopausal osteoporosis
- PMID: 1581279
- DOI: 10.1111/j.1471-0528.1992.tb13732.x
Compliance with hormone replacement therapy (HRT) after screening for post menopausal osteoporosis
Abstract
Objective: To assess compliance with recommendations for hormone replacement therapy (HRT) in postmenopausal women following screening for osteoporosis.
Design: A postal questionnaire sent to women an average of 8 months (range 6-12) following measurement of their bone mineral density (BMD), and recommendations regarding HRT given to the referring general practitioner.
Setting: Referrals from local general practitioners. Mixed social class.
Subjects: 400 postmenopausal women aged 40-69 years (average age 52).
Main outcome measures: Compliance with advice and if failing to comply, reasons for not doing so.
Results: Replies were received from 352 women (88%) and 74% of respondents followed advice to start, continue, or refrain from starting or continuing HRT with regard to protecting their skeleton. Those who rejected advice to take HRT mostly had concern over side effects or the efficacy or safety of treatment. Of the women who started HRT 28% subsequently stopped, the principal reasons being withdrawal bleeding and weight gain. Of the women recommended to take HRT, 39% were not taking treatment by 8 months after referral, either because they ignored advice given (22%) or because of side effects (17%).
Conclusions: Screening leads to increased usage of HRT among women at most risk for osteoporosis. However, almost 40% of women with low bone mineral density were not taking HRT 8 months after referral, and therefore until improved compliance has been demonstrated screening cannot be widely recommended.
Comment in
-
Compliance with hormone replacement therapy (HRT) after screening for post menopausal osteoporosis.Br J Obstet Gynaecol. 1993 Apr;100(4):399-400. doi: 10.1111/j.1471-0528.1993.tb12996.x. Br J Obstet Gynaecol. 1993. PMID: 8494850 No abstract available.
Similar articles
-
Hormone replacement therapy: compliance and cost after screening for osteoporosis.Eur J Obstet Gynecol Reprod Biol. 1995 Mar;59(1):57-60. doi: 10.1016/0028-2243(94)02002-v. Eur J Obstet Gynecol Reprod Biol. 1995. PMID: 7781863
-
Compliance considerations with hormone replacement therapy.Menopause. 1998 Summer;5(2):102-6. Menopause. 1998. PMID: 9689204
-
Initiation of hormone replacement therapy after diagnosis of osteoporosis by bone densitometry.Osteoporos Int. 1997;7(2):162-4. doi: 10.1007/BF01623693. Osteoporos Int. 1997. PMID: 9166398
-
Hormone replacement therapy: II. A pharmacoeconomic appraisal of its role in the prevention of postmenopausal osteoporosis and ischaemic heart disease.Pharmacoeconomics. 1994 Jun;5(6):513-54. doi: 10.2165/00019053-199405060-00007. Pharmacoeconomics. 1994. PMID: 10147266 Review.
-
A review of bone mineral density scans referred by a community-based menopause clinic in 1997.Br J Fam Plann. 2000 Jul;26(3):136-8. doi: 10.1783/147118900101194553. Br J Fam Plann. 2000. PMID: 10920288 Review.
Cited by
-
Impact of multidisciplinary collaborative pharmaceutical care on knowledge, adherence, and efficacy of hormone therapy in climacteric women.Patient Prefer Adherence. 2018 Jul 19;12:1273-1278. doi: 10.2147/PPA.S165238. eCollection 2018. Patient Prefer Adherence. 2018. PMID: 30050289 Free PMC article.
-
Hormone replacement therapy. Risks, benefits, and costs.Can Fam Physician. 1993 Oct;39:2149-54. Can Fam Physician. 1993. PMID: 8219862 Free PMC article. Review.
-
Predictors of compliance with a home-based exercise program added to usual medical care in preventing postmenopausal osteoporosis: an 18-month prospective study.Osteoporos Int. 2005 Mar;16(3):325-31. doi: 10.1007/s00198-004-1697-z. Epub 2004 Jul 29. Osteoporos Int. 2005. PMID: 15726237
-
Women's use of hormone replacement therapy for relief of menopausal symptoms, for prevention of osteoporosis, and after hysterectomy.Br J Gen Pract. 1995 Jul;45(396):355-8. Br J Gen Pract. 1995. PMID: 7612339 Free PMC article.
-
Economic evaluation of norethisterone acetate/ethinylestradiol (FemHRT) for women with menopausal symptoms.Pharmacoeconomics. 2003;21(9):661-9. doi: 10.2165/00019053-200321090-00004. Pharmacoeconomics. 2003. PMID: 12807367
MeSH terms
LinkOut - more resources
Medical